Arrival moment
Why Tel Aviv owners arrive here.
The Tel Aviv business is real. Standing inside the Check Point and CyberArk-trained founder pool, the Unit 8200 ecosystem, the Mobileye-adjacent infrastructure tier, the Insightec, Lumenis, and Nano-X medtech adjacency, the Teva-adjacent biotech tier, and the Israeli founder-led venture cohort has been earned through technical depth, founder velocity, and global category-creation at scale. Revenue is on the board. The decision is made to put commercial weight into the US market. A US-incorporated parent is in place. A Boston or Bay Area office is open. A US revenue gap appears that does not match the team caliber, the product, or the venture round.
The instinct is to lead with technology novelty, founder story, and traction milestones. The instinct is right at home and wrong for the American buyer's procurement buyer. The Israeli register over-indexes on novelty and under-indexes on US category, US peer set, and US procurement-risk answers. "Israeli unicorn" lands as a category in Israel and as a flag in the US. US enterprise, federal-adjacent, and clinical buyers do not buy on novelty. They buy on a defined US category, a US peer set they already trust, and a procurement-risk picture they can clear internally without flagging the deal up the chain.
American buyers sort fast on three signals: category anchor, US peer set, and procurement-risk answers. Tel Aviv materials tend to lead with founder narrative, technology novelty, and Israeli-ecosystem proof. The work is to translate the Israeli identity into US-legible sales and marketing system without flattening what carries at home. The issue is rarely product or talent, almost always sales story on US website, deck, and sales materials.
The American buyer is not asking for less novelty. They are asking for the US category, the US peer set, and a procurement-risk picture they can clear without escalation. Tel Aviv firms lead with the founder story and omit the rest.
House view on Tel Aviv to US entry